BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock enjoyed a major increase of 25.6% on 1/8/24. The shares closed at $7.65. Moreover, trading volume in this advance was exceptionally high at 286% of normal. Relative to the market the stock has been weak over the last nine months but has risen 25.6% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment